Table 2.
Age-standardized characteristics of participants with PCa by ERG and PTEN status, the Health Professionals Follow-up Study, 1990-2009
| Cases by ERG status | Cases by PTEN status | |||||
|---|---|---|---|---|---|---|
| Characteristic | Positive | Negative | Unavailable | Null | Intact | Unavailable |
| N | 417 | 471 | 4,623 | 100 | 615 | 4,796 |
| Mean age at diagnosis, years (SD)a | 65.2 (6.1) | 66.2 (5.7) | 70.9 (7.5) | 66.4 (6.3) | 65.7 (5.9) | 70.7 (7.5) |
| Year of diagnosis | ||||||
| 1990-1994 | 34.7% | 27.9% | 21.5% | 32.9% | 26.0% | 22.3% |
| 1995-1999 | 36.3% | 33.1% | 25.3% | 39.8% | 28.6% | 26.4% |
| 2000-2004 | 15.0% | 25.2% | 30.4% | 16.9% | 26.3% | 29.4% |
| 2005-2009 | 14.0% | 13.7% | 22.8% | 10.4% | 19.0% | 21.9% |
| Mean PSA at diagnosis (SD)b | 9.9 (10.8) | 10.0 (11.1) | 15.5 (117) | 9.4 (7.8) | 9.9 (11.2) | 15.4 (116) |
| % Missing | 5.6% | 9.5% | 16.0% | 13.9% | 6.8% | 15.8% |
| TNM clinical stage | ||||||
| T1 / T2b | 93.4% | 96.0% | 92.8% | 92.1% | 96.0% | 92.9% |
| T3b | 4.7% | 2.0% | 2.8% | 2.3% | 3.3% | 2.8% |
| T4 / N1 / M1b | 1.9% | 2.0% | 4.4% | 5.6% | 0.7% | 4.3% |
| % Missing | 0.0% | 0.0% | 11.8% | 0.0% | 0.0% | 11.5% |
| Gleason grade | ||||||
| Gleason 2-6b | 58.1% | 59.0% | 61.5% | 33.1% | 60.5% | 61.7% |
| Gleason 3+4b | 19.1% | 16.9% | 16.1% | 21.0% | 17.9% | 16.1% |
| Gleason 4+3b | 12.0% | 12.6% | 7.5% | 17.4% | 12.8% | 7.5% |
| Gleason 7, breakdown unknownb | 1.5% | 0.7% | 3.7% | 3.7% | 0.2% | 3.6% |
| Gleason 8-10b | 9.3% | 10.8% | 11.2% | 24.8% | 8.7% | 11.0% |
| % Missing | 0.0% | 0.1% | 15.3% | 0.0% | 0.1% | 14.8% |
| Lethal PCa | 9.6% | 8.8% | 14.2% | 24.8% | 5.0% | 14.1% |
| Family history of PCa | 21.6% | 21.8% | 20.0% | 25.7% | 19.8% | 20.2% |
| Father with PCa | 14.3% | 16.7% | 15.4% | 14.8% | 15.2% | 15.5% |
| Brother(s) with PCa | 8.5% | 6.2% | 5.9% | 12.3% | 5.5% | 6.0% |
| Earliest age at family member PCa diagnosisc | ||||||
| Age <60 years | 14.0% | 5.9% | 10.3% | 15.3% | 5.3% | 10.5% |
| Age 60+ years | 59.1% | 63.2% | 63.1% | 58.6% | 63.7% | 63.0% |
| Age unknown | 26.9% | 30.8% | 26.6% | 26.1% | 31.0% | 26.5% |
Abbreviations: PCa, prostate cancer; PSA, prostate-specific antigen; SD, standard deviation
a
Value is not age-standardized
b
Values are among those with data available
c
Among cases with a positive family history of PCa